#USA #Chicago #D3 Bio #elisrasib #ASCO 2026

D3 Bio Unveils First-Line Data for Elisrasib at ASCO 2026

D3 Bio Inc., a biotechnology company committed to advancing innovative cancer treatments, presented encouraging findings regarding their drug, Elisrasib (D3S-001), at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago in May 2026. Attendees were presented with data showcasing both monotherapy and combination therapy strategies for treating non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation.

Elisrasib Monotherapy Outcomes

Elisrasib, administered as a standalone treatment, showed remarkable efficacy in patients who had never received treatment for KRAS G12C-mutated NSCLC. Out of 43 patients included in the study, a striking overall response rate (ORR) of 78% was recorded among those evaluated for efficacy. This outcome is noteworthy across all levels of PD-L1 expression, providing new hope for patients who witness varied responses to existing therapies. Of the 41 patients evaluated, 76.2% with PD-L1 less than 1% and 80% with PD-L1 greater than or equal to 1% responded positively to the treatment. Additionally, the disease control rate (DCR) stood at an impressive 95.1%.

The median progression-free survival (mPFS) was achieved at 12.4 months, indicating that patients had a significant duration free from disease progression. Encouragingly, the median overall survival (OS) has not yet been established, but a 90% rate was observed at the 12-month mark for those participating in the study. Notably, the treatment was well-tolerated, with only 7% of patients experiencing severe treatment-related adverse events (TRAEs) and no cases leading to discontinuation of the drug.

Combination Therapy: Elisrasib and Pembrolizumab

Elisrasib was further evaluated in combination with Pembrolizumab, an established immunotherapy agent, among 52 previously untreated patients. The combination therapy achieved an ORR of 81.3%, exhibiting even higher efficacy across diverse PD-L1 expression levels. Specifically, patients with PD-L1 less than 1% saw a response rate of 70.6%, while those with PD-L1 over 50% had an outstanding response rate of 95%. The findings underline the potential of this combined treatment approach, enhancing the prospects for patients who might benefit from synergistic effects.

The study recorded a DCR of 97.9%, showcasing the combination's ability to effectively manage disease progression. The combination therapy's safety profile remained consistent with those known for the individual agents, with 32.7% of patients observed with severe TRAEs, predominantly attributed to Pembrolizumab. This points towards the manageable nature of side effects associated with this treatment approach.

Expert Insights

Prof. Shun Lu, an influential figure in oncology from Shanghai Chest Hospital, emphasized the encouraging results of Elisrasib's first-line usage, noting its strong anti-tumor activity among varied PD-L1 expression groups. This further suggests the drug's potential to be integrated into standard treatment protocols for KRAS G12C-mutant NSCLC. Dr. George Chen, CEO of D3 Bio, echoed this sentiment, expressing confidence in progressing to Phase 3 randomized studies based on the compelling activity observed in the first-line treatment setting.

About Elisrasib

Elisrasib is touted as a next-generation KRAS G12C inhibitor, designed for precise target engagement. Its unique mechanism of action involves binding to the OFF form of KRAS G12C, halting its oncogenic signaling while showcasing remarkable CNS penetration capabilities in preliminary studies. As more data emerge, the drug's potential for groundbreaking impact in oncology continues to gain traction.

With its innovative approach and robust early data, Elisrasib stands poised to redefine treatment options for patients battling KRAS G12C-mutant cancers. D3 Bio remains committed to advancing this promising candidate through further clinical evaluations, thus paving the way for enhanced therapeutic designs in cancer care.